Jefferies Maintains $36 PT On AUXL

Jefferies is maintaining its $36 PT on shares of Auxilium Pharmaceuticals, Inc. AUXL. “Xiaflex continues to be the main stock driver for AUXL,” Jefferies writes. “We believe Xiaflex adoption is gated by reimbursement concerns rather than clinical concerns, and we anticipate steady Xiaflex sales growth in 2011 with sales acceleration in 2012.” Auxilium Pharmaceuticals closed Friday at $22.32.